VLP-001 is under clinical development by Allergy Therapeutics and currently in Phase II for Peanut Allergy. According to GlobalData, Phase II drugs for Peanut Allergy have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VLP-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VLP-001 overview
Polyvac peanut vaccine is under development for the prevention of peanut allergy. The vaccine candidate is administered by subcutaneous and intravenous route. It consists of a recombinant peanut allergen coupled with a virus-like particle (VLP) adjuvant. It is developed based on virus-like particles (VLP) technology.
Allergy Therapeutics overview
Allergy Therapeutics is a specialty pharmaceutical company that develops therapies for allergy treatment and allergy prevention. The company offers a wide range of aluminum-free allergy vaccines and diagnostics. Allergy Therapeutics product portfolio includes Grass Modified Allergen Tyrosine Adsorbed (MATA), Tree MATA, Ragweed MATA, Bee Venom Subcutaneous Immunotherapy (SCIT), and Wasp venom SCIT among others. It also offers allergen extracts used for skin prick testing. The company’s diagnostics products comprise of Pollen, Moulds, Arthropods, Epithelia and others. It has operational presence in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the UK among others. Allergy Therapeutics is headquartered in Worthing, West Sussex, the UK.
For a complete picture of VLP-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
